Cartesian Therapeutics Inc
RNAC - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$196.36M
Close$
$3.73
41.1% downside
Current Fair Value
41.1% downsideOvervalued by 41.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $196.36 Million |
|---|---|
| Enterprise Value | $66.56 Million |
| Earnings per Share | $-5.02 |
| Beta | 0.65 |
| Outstanding Shares | 29,467,130 |
Return
| Return on Equity | 122.93% |
|---|---|
| Return on Assets | -48.31% |
| Return on Invested Capital | -10.67% |
Valuation & Multiples
| P/E Ratio | -1.09 |
|---|---|
| PEG | 8.03 |
| Price to Sales | - |
| Price to Book Ratio | -1.27 |
| Enterprise Value to Revenue | 45.06 |
| Enterprise Value to EBIT | -2.09 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | -0.14 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.88
Consensus analyst estimateRevenue Estimate
$179,667
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.02
Consensus analyst estimateRevenue Estimate
$160,000
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 21.77% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 29.60% |
|---|---|
| Total Invested | $11,094▼ 99.99% |
| Investors Holding | 5▼ 96.00% |
About Cartesian Therapeutics Inc
81 employees
CEO: Carsten Brunn
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vac...